ValuEngine cut shares of Versartis, Inc. (NASDAQ:VSAR) from a sell rating to a strong sell rating in a research note released on Friday.

Several other equities analysts have also recently commented on the stock. Piper Jaffray Companies reissued a buy rating and issued a $26.00 price target on shares of Versartis in a research report on Friday, September 8th. Cantor Fitzgerald set a $34.00 price target on shares of Versartis and gave the company a buy rating in a research report on Thursday, July 27th. BidaskClub raised shares of Versartis from a hold rating to a buy rating in a research report on Monday, July 24th. Zacks Investment Research raised shares of Versartis from a sell rating to a hold rating in a research report on Thursday, June 29th. Finally, Canaccord Genuity set a $28.00 price target on shares of Versartis and gave the company a buy rating in a research report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $18.22.

Shares of Versartis (VSAR) traded down 87.616% during mid-day trading on Friday, hitting $2.675. The company had a trading volume of 40,104,166 shares. The firm’s market capitalization is $95.17 million. Versartis has a 52-week low of $2.60 and a 52-week high of $24.00. The firm has a 50-day moving average price of $18.37 and a 200 day moving average price of $18.36.

Versartis (NASDAQ:VSAR) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.20). Analysts expect that Versartis will post ($3.54) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Versartis, Inc. (VSAR) Downgraded by ValuEngine to Strong Sell” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/09/23/versartis-inc-vsar-downgraded-by-valuengine-to-strong-sell.html.

Institutional investors and hedge funds have recently made changes to their positions in the company. First Quadrant L P CA acquired a new stake in shares of Versartis in the 2nd quarter valued at $155,000. Bank of America Corp DE raised its holdings in shares of Versartis by 46.3% in the 1st quarter. Bank of America Corp DE now owns 9,482 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 3,001 shares in the last quarter. Tudor Investment Corp ET AL acquired a new stake in shares of Versartis in the 2nd quarter valued at $218,000. Numeric Investors LLC acquired a new stake in shares of Versartis in the 2nd quarter valued at $246,000. Finally, Voya Investment Management LLC raised its holdings in shares of Versartis by 26.1% in the 2nd quarter. Voya Investment Management LLC now owns 14,960 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 3,094 shares in the last quarter. Institutional investors and hedge funds own 78.24% of the company’s stock.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Analyst Recommendations for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.